Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
Share
Why It Matters
Biohaven just got paid $100 million by a company in Asia. This shows that other companies think Biohaven's medicine ideas are worth real money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.